Leading Beyond The Lab

95% of our viewers aren't subscribed. If you're watching and not yet subscribed, please subscribe to the channel so you don't miss future episodes. What does it take to improve a drug discovery success rate of less than 1%? In this episode, Yann Gaston-Mathé explains how AI, robotics, and laboratory automation are being combined to accelerate the development of new medicines and tackle some of the...

95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes. Can targeting IRhom2 unlock a new generation of autoimmune disease treatments? This week on Leading Beyond The Lab, Lawrence Rose sat down with Jan Poth and Jens Ruhe of SciRhom, discussing a new therapeutic approach focused on IRhom2 and TACE inhibiti...

95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes. This week on Leading Beyond The Lab, Lawrence Rose sat down with Megan McGill, CEO of Brenig Therapeutics, with years of experience spanning biotech leadership, strategy, clinical medicine, management consulting and neuroscience research. In this episo...

95% of our viewers aren’t subscribed. If you’re watching and not yet subscribed, please subscribe to the channel so you don’t miss future episodes. Can AI become a universal simulator of biology, helping predict disease, improve drug success rates, and reshape how medicine is developed? This week on Leading Beyond The Lab, Lawrence Rose sat down with Jean-Philippe Vert, Co-Founder and CEO of Biopt...

What does it take to build not just one billion-dollar company, but seven and start again after losing it all? In this episode, Robert Wessman shares the mindset, discipline and foresight behind building one of the world’s most ambitious biosimilars platforms. This week on Leading Beyond The Lab, Lawrence Rose sat down with Robert Wessman, Founder and Executive Chairman, with over 25 years of expe...

AI is beginning to uncover medicines that humans alone could never design. This week on another episode of Leading Beyond the Lab, we host James Field, CEO and Founder of LabGenius Therapeutics, a company pioneering the use of machine learning, robotics, and synthetic biology to engineer the next generation of therapeutic antibodies. With over a decade of experience spanning AI-driven drug discove...

90% of our listeners don't realise they aren't subscribed - please check! What if we could predict whether a drug will work, before it ever reaches a patient? This week, in another episode of Leading Beyond the Lab, we host a co-guest episode featuring Nik Sharma, CEO & Co-Founder of BioCortex, a trained neurologist with years of experience spanning clinical medicine, ALS research, academia (C...

What if a single injection could teach the immune system to eliminate cancer, and keep it away? This week, in another episode of Leading Beyond the Lab, Lawrence Rose sits down with Paul Peter Tak, MD, PhD, FMedSci, President & CEO of Candel Therapeutics, one of the most quietly compelling stories in cancer immunotherapy today. With over 30 years of experience spanning academic medicine, clini...

If AI is collapsing the cost of healthcare — are we on the brink of a historic breakthrough… or another bubble? This week on Leading Beyond the Lab, we sit down with @Edward Kliphuis, Partner at @Sofinnova Partners, one of Europe’s leading life-sciences venture capital firms. With over 20 years of experience spanning venture capital, digital health, tech-bio investing, and global life-sciences str...

From science fiction to clinical reality. What happens when cell therapy moves from promise to proof in patients who have run out of options? This week on Leading Beyond the Lab, Lawrence Rose sat down with Amit Rakhit, Chief Medical Officer at BlueRock Therapeutics, to explore how regenerative medicine, leadership, and culture intersect at the most pivotal stages of biotech development. A physici...

97% of our viewers don't realise they aren't followed, please double check, thank you! What does it really take to back and build world-class biotech companies from idea to FDA approval? This week on Leading Beyond the Lab, Lawrence Rose sat down with Jonathan Tobin, Partner at Brandon Capital, to explore what truly drives success in life-science venture capital. With over 20 years' experience spa...

This episode is a masterclass in how world-class life sciences investors think about risk, conviction, and real patient impact. This week on Leading Beyond The Lab, Lawrence Rose sat down with Nikhil Thatte, Partner at Lumira Ventures, a leading Canadian life sciences venture capital firm, with over a decade of experience backing transformative biotech and medtech companies across North America. I...

Cardio-metabolic diseases are the world’s biggest killer. But what if the next generation of treatments could change everything? This week on Leading Beyond The Lab, Lawrence Rose sat down with Jyothis George, CMO of Nodthera, and a global thought leader in the obesity space, shaping the future of cardio-metabolic and inflammatory disease innovation. Jyothis has led global programs across GLP-1, S...

25 years of life sciences venture experience in one episode. This week on Leading Beyond The Lab, @Lawrence Rose sat down with @Joey Mason, a venture investor with 25 years of experience across venture debt, venture capital and company building. Joey’s background spans senior roles with @Claret Capital Partners, @Sofinnova Partners, and earlier positions in investment banking and CRO services. His...

🤔 What does it really take to build a biotech that survives the clinical gauntlet and scales into a global business? 🎬 This week on Leading Beyond The Lab, Lawrence Rose sat down with Roel Bulthuis, Managing Partner and Head of Investments at Syncona Limited. Roel has spent his career building, funding and scaling European biotech companies end-to-end, supporting high-performing teams from incep...

A once-in-a-century transformation, and the leader driving it. This week, in one of our biggest episode of Leading Beyond the Lab yet, we sit down with Christophe Bourdon, CEO of LEO Pharma, a company valued in the multi-billion-euro range and entering one of the most defining chapters in its 100-year history. With over 25+ years of global biopharma leadership experience , spanning pivotal roles a...

What does it take to shape a high-impact biotech investment portfolio - and do it under a medical charity mandate? This week we sit down with Clare Terlouw, Head of LifeArc Ventures, whose 20+ year career spans investment banking, biotech company building, and leading venture teams focused on health innovation. With a unique perspective at the intersection of science, capital, and patient impact,...

If you're not paying attention to nuclear medicine, Danielle Meyrick will change that in under five minutes. This week, we sit down with Dr. Danielle Meyrick, Director and Co-Founder at EPIC Theranostics, to explore the meteoric rise of nuclear medicine and radiotheranostics. With over 20 years of experience spanning academia, biotech, and hospital environments, Danielle is uniquely positioned as...

Two of the most influential minds in immuno-oncology walk into a biotech… and build something that could change everything. Dr. Rachel Humphrey (CEO) and Dr. Melinda Merchant (CMO) of Normunity are two of the most seasoned and respected leaders in oncology drug development, with a combined 45+ years of experience across big pharma, biotech, and translational science. Rachel led the development of...

Dr. Arndt Schottelius, CEO of Maxion Therapeutics, is a physician-scientist with a standout career across Genentech, MorphoSys, Kymab, and now at one of the UK’s most promising biotech companies. At Maxion, he leads a team pioneering KnotBody technology - an innovative approach to targeting ion channels and GPCRs, long considered “undruggable” with biologics. Arndt brings more than 25 years of exp...

If you want to understand what it really takes to build and lead a successful biotech, this episode is for you. Dr. Christopher Morabito, Chief Medical Officer at Astria Therapeutics, joins us to share hard-won lessons from 25 years in rare disease, oncology, and immunology. But this isn’t a career retrospective - it’s a deep dive into the mindset, strategies, and leadership habits that drive biot...

If you're in biotech, immunology, or drug development - this is the episode you’ve been waiting for. We’re joined by Dr. Bhaskar Srivastava, Chief Medical Officer at Triveni Bio, whose career has spanned over 10 years across J&J, Nimbus, and now Triveni Bio, one of the most ambitious autoimmune biotech startups on the scene. In this episode, Bhaskar dives deep into: · How Triveni is building a...

If you care about the future of genomics, diagnostics, and biotech investing, you can’t miss this episode. We’re joined by Mara Aspinall, Partner at Illumina Ventures, a trailblazer with over 30 years of leadership in diagnostics and eight years in venture capital funding groundbreaking genomics companies. In this episode, Mara reveals: The next wave of diagnostics, from liquid biopsies to home te...

To anyone interested in life science VC investment – you need to watch this. In this episode, we’re joined by Dr. Sascha Berger, a biotech investment director based in Saudi Arabia and a very experienced life science investor globally. With nearly two decades in the industry, he’s seen breakthroughs, pivots, and billion-dollar transactions. He reveals: Saudi Arabia’s high-stakes plan to become a g...

In this episode, we sit down with Dr. Tomoko Maeda-Chubachi - a global leader in dermatology drug development and biotech innovation: Dr. Maeda-Chubachi serves as fractional Chief Medical Officer at various startups focusing on dermatology indications. 20+ years experience in the pharmaceutical industry, Dr. Maeda-Chubachi has held senior roles at major companies like Pfizer, Eli Lilly, and GSK. H...